Search company, investor...

NeoVista

neovistainc.com

Founded Year

2002

Stage

Series E | Dead

Total Raised

$125.64M

Last Raised

$5.18M

About NeoVista

NeoVista is developing medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). The company's technology utilizes highly targeted strontium 90 beta radiation in a one-time surgical procedure. This technology is under investigation in clinical trials and has the potential to reduce the burden that wet AMD places on healthcare providers, patients, and the healthcare system.

Headquarters Location

38875 Cherry Street

Newark, California, 94560,

United States

510-933-7600

Missing: NeoVista's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NeoVista's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

NeoVista Patents

NeoVista has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/27/2010

2/5/2013

Radiation therapy, Diseases of the eye and adnexa, Radioactivity, Radiobiology, Medical physics

Grant

Application Date

8/27/2010

Grant Date

2/5/2013

Title

Related Topics

Radiation therapy, Diseases of the eye and adnexa, Radioactivity, Radiobiology, Medical physics

Status

Grant

Latest NeoVista News

Two-year data do not support epimacular brachytherapy for wet AMD

Aug 28, 2020

Disclosures: Jackson reports he received an unrestricted educational grant from NeoVista and support from the NIHR Clinical Research Network during the conduct of the study; received personal fees from Opthea, free use of medical device from Zeiss/Oraya and site payments to his employer from Roche and Novartis outside the submitted work; and served as chief investigator in an NIHR-funded clinical trial of stereotactic radiotherapy for wet age-related macular degeneration. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Two-year results of the MERLOT trial showed no benefit of epimacular brachytherapy as an adjunct to anti-VEGF injections. In fact, the combined therapy group had worse results overall compared with the ranibizumab monotherapy group. The attempt to combine anti-VEGF injections with epimacular brachytherapy (EMB) was driven by the hypothesis that targeted radiation might help reduce the overall number of injections without sacrificing visual acuity outcomes. One-year results did not support the use of EMB. However, because the full effect of radiation and radiation damage takes time to manifest, the 12-month results were not judged to be sufficient to establish the safety and efficacy of this method. Timothy Jackson, PhD, FRCOphth The MERLOT study enrolled 363 participants with active neovascular age-related macular degeneration in 24 NHS hospitals in the U.K. They were randomly assigned 2:1 to receive either EMB plus ranibizumab as needed or ranibizumab as needed as monotherapy; 329 patients (90.6%) completed the 24-month follow-up. At month 24, visual acuity outcomes were significantly worse in the EMB group, with a mean change in best corrected visual acuity of –11.2 letters from baseline as compared with –1.4 letters in the ranibizumab monotherapy group. Anatomic outcomes mirrored the decline in vision, with an increase of 7 µm in foveal thickness in the EMB group as compared with a decrease of –20 µm in the ranibizumab group, as well as an increase of 4.1 mm2 in total lesion size in the EMB group vs. 2.1 mm2 in the ranibizumab monotherapy group. Adverse events were also more frequent in the EMB group but consistent with the known effects of vitrectomy, with more than a threefold greater incidence of cataract. Microvascular abnormalities were reported in 9.7% of the EMB group vs. 1% of the ranibizumab monotherapy group, but these were often subtle, and none involved the foveal center. Interestingly, the goal of reducing the number of injections by combining ranibizumab with radiation was not achieved. The total number of injections from month 1 to month 24 inclusive was 9.3 in the EMB group vs. 8.3 in the ranibizumab group. “These results do not support the use of epimacular brachytherapy for chronic, active wet AMD, as it did not reduce the number of anti-VEGF injections that patients required, and vision was worse,” Timothy Jackson, PhD, FRCOphth, first author of the study, told Healio/OSN. Although the EMB device used in the study has marketing authorization in Europe, he does not see a role for EMB in the emerging treatment landscape. An alternative could be stereotactic radiotherapy (SRT), which used a robotically controlled system in the randomized, double-masked, sham-controlled INTREPID study. “We used SRT in combination with ranibizumab as needed in patients with wet AMD and found very different results. Participants required significantly fewer anti-VEGF injections than the control group, with better vision in selected subgroups,” Jackson said. “This may be because radiation delivery was very precise using eye tracking software, and patients did not require vitrectomy, which reduces the half-life of intravitreal anti-VEGF drugs.” Accordingly, the U.K.’s National Institute for Health Research is funding the STAR trial, in which 411 patients are randomly assigned to receive SRT or placebo. They will be followed up regularly for 2 years and again checked for safety at the end of 3 and 4 years. Results are expected in the first half of 2022.

NeoVista Frequently Asked Questions (FAQ)

  • When was NeoVista founded?

    NeoVista was founded in 2002.

  • Where is NeoVista's headquarters?

    NeoVista's headquarters is located at 38875 Cherry Street, Newark.

  • What is NeoVista's latest funding round?

    NeoVista's latest funding round is Series E.

  • How much did NeoVista raise?

    NeoVista raised a total of $125.64M.

  • Who are the investors of NeoVista?

    Investors of NeoVista include Carlyle, MPM Capital, Innovation Factory, Versant Ventures, Oxford Finance and 7 more.

  • Who are NeoVista's competitors?

    Competitors of NeoVista include MedShape, Cardiva Medical, eNeura Therapeutics, Inspire Medical Systems, InnoMed Technologies and 12 more.

Compare NeoVista to Competitors

N
Novasys Medical

Novasys Medical, formerly Genesis Medical, is a medical device company that develops therapies in women's health. The company's initial focus is the development and commercialization of the Renessa System, a non-surgical approach to the treatment of female stress urinary incontinence (SUI). The company was founded in 1999 and is based in Newark, California.

C
C2C

C2C is a medical device company developing a portfolio of medical devices.

C
Carticept Medical

Carticept Medical, formerly Windward Medical, is a medical device company dedicated to improving the quality of life for patients with osteoarthritis or cartilage damage through the development of therapies.

e
eNeura Therapeutics

eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.

O
Ovalis

Ovalis was formed by several highly experienced device engineers to develop a set of interventional devices and delivery systems useful for the repair of various cardiovascular defects.

E
Es Vascular

ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.